Analysts Recommend “Moderate Buy” for Sotera Health Stock

Sotera Health Company (NASDAQ: SHC) has received a consensus recommendation of “Moderate Buy” from five research firms currently tracking the stock, according to a report from Marketbeat.com. Among the analysts, one has assigned a hold rating while four others have given it a buy recommendation. The average price target for Sotera Health over the next year stands at $16.00.

Recent Performance and Analyst Upgrades

The company’s stock has garnered attention following its recent earnings announcement. On August 8, 2023, Sotera Health reported earnings of $0.20 per share for the quarter, surpassing the consensus estimate of $0.17 by $0.03. Revenue for the same period reached $294.34 million, exceeding expectations of $275.81 million. The firm also noted a net margin of 2.14% and a strong return on equity of 39.42%.

These figures reflect a year-over-year revenue increase of 6.4%, compared to $0.19 earnings per share in the previous year. Sotera Health has set a fiscal year 2025 guidance of $0.750-0.820 earnings per share, with analysts anticipating $0.61 earnings per share for the current fiscal year.

In addition to the favorable earnings report, Sotera Health has seen upgrades from analysts. Notably, Wall Street Zen raised its rating for the company from “buy” to “strong-buy” on August 16, 2023. Barclays has reiterated its “overweight” rating for the stock as well.

Insider Transactions and Institutional Investments

Recent insider activity has also been noteworthy. On August 22, 2023, insider Michael P. Rutz sold 126,611 shares of Sotera Health at an average price of $16.38, totaling approximately $2,073,888.18. This sale decreased Rutz’s ownership to 450,204 shares, valued at around $7,374,341.52, representing a 21.95% reduction in his stake.

Further, Gtcr Investment Xi LLC, a director at the company, sold 8,000,000 shares on September 5, 2023, at an average price of $15.11, yielding a total transaction of $120,880,000. Post-sale, this director holds 41,215,301 shares, valued at approximately $622,763,198.11, marking a 16.26% decrease in ownership.

In terms of institutional investments, several firms have adjusted their holdings in Sotera Health. The State of Wyoming increased its position by 420.6% during the second quarter, acquiring an additional 53,397 shares, bringing its total to 66,092 shares valued at $735,000.

Vident Advisory LLC also raised its stake by 23.9%, while Sculptor Capital LP increased its holdings by 27.2%, now owning 11,500,000 shares valued at approximately $127,880,000. Overall, institutional investors and hedge funds own 91.03% of Sotera Health’s stock.

Sotera Health operates in the sterilization, lab testing, and advisory services sectors, catering to both domestic and international markets. Its operations are divided into three segments: Sterigenics, Nordion, and Nelson Labs, providing essential sterilization services including gamma and electron beam irradiation, as well as ethylene oxide processing.

As the company navigates its recent performance and market recommendations, stakeholders will be closely watching further developments and strategic decisions that may influence its trajectory in the coming months.